GERON CORP Impairment of Long-Lived Assets Held-for-use
GERON CORP (GERN) reported Impairment of Long-Lived Assets Held-for-use of $200.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2016-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2016-03-10
- GERON CORP impairment of long-lived assets held-for-use for the quarter ending 2013-12-31 was $0.00.
- GERON CORP impairment of long-lived assets held-for-use for the quarter ending 2013-09-30 was $0.00.
- GERON CORP impairment of long-lived assets held-for-use for fiscal 2013 was $200.00K, a 26.20% decline from fiscal 2012.
- GERON CORP impairment of long-lived assets held-for-use for fiscal 2012 was $271.00K, a 68.99% decline from fiscal 2011.
- GERON CORP impairment of long-lived assets held-for-use for fiscal 2011 was $874.00K.
- GERON CORP impairment of long-lived assets held-for-use for fiscal 2010 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $0.00 derived: sum of 2 quarters · filed 2016-03-10 | $200.00K 10-K · filed 2016-03-10 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $200.00K 10-Q · filed 2014-11-05 | ||
| 2013-06-30 | $200.00K 10-Q · filed 2014-08-11 | |||
| 2012-12-31 | $271.00K 10-K · filed 2015-03-11 | |||
| 2011-12-31 | $874.00K 10-K · filed 2014-03-17 | |||
| 2010-12-31 | $0.00 10-K · filed 2012-03-07 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |